Open Access
Table II
Critical analysis of the literature on the efficacy of botulinum toxin in the management of mouth opening limitation.
Reference | Objective | Type of study | No. | BT dose | Duration | Judgment criteria | Muscle site | Validity |
---|---|---|---|---|---|---|---|---|
Fietzek, 2009 [14] | Efficiency: MO increase | Rand, DB, CT 2 centers | 11 | 5000 U Neurobloc** | 6 weeks | Objective: IDS, saliva rate, MO | M | S |
Guarda-Nardini, 2012 [15] | Efficacy: decrease in pain and increase MO | Rand, CT; SB | 30 | 150 U Dysport* | 3 months | Subjective: VAS | M + T | S |
Objective: MO | S | |||||||
Kurtoglu, 2010 [16] | Efficiency: decreased pain and increased MO | Rand, DB, CT | 24 | 30 U Botox* | 1 month | Subjective: VAS | M + T | S |
Objective: MO with EMG | S | |||||||
Denglehem, 2010 [17] | Efficacy: decreased pain | Rand, DB, CT | 30 | 50 U Botox* | 1 month | Subjective: VAS with pressure | M + T | S |
Objective: Muscular activity with EMG | S | |||||||
Sidebottom, 2012 [18] | Efficiency: decreased pain and increased MO | Prospective, statistical analysis | 62 | 50 U Dysport* | 3 weeks | Subjective: VAS | M + T + P | S |
Objective: MO | S |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.